AstraZeneca plc using EPIC/TICKER code (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OUTPERFORM’ today by analysts at Credit Suisse. AstraZeneca plc are ...

Stock in Anglo Pacific Group ticker lookup code: LON:APF has stepped up 4.91% or 9.42 points during today’s session so far. Buyers are a positive bunch during the session. The ...

AstraZeneca (LON:AZN) has completed an agreement to divest its commercial rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. Financial considerations Under the terms of the agreement, AstraZeneca ...

AstraZeneca plc using EPIC/TICKER code (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Deutsche Bank. AstraZeneca plc are ...

AstraZeneca (LON:AZN) has today announced that it has received marketing authorisation from China’s National Medical Products Administration for Imfinzi for the treatment of patients with unresectable, Stage III non-small cell lung cancer ...

Stock in Anglo Pacific Group ticker lookup code: LON:APF has stepped up 6.28% or 11.5 points throughout the session so far. Traders have so far held a positive outlook during ...

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the companies have received marketing authorisation from ...

AstraZeneca (LON:AZN) has agreed to sell the commercial rights to Seroquel and Seroquel XR in the US and Canada to Cheplapharm Arzneimittel GmbH. Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their ...

AstraZeneca (LON:AZN) today announced that the US Food and Drug Administration has accepted a supplemental Biologics License Application and granted Priority Review for Imfinzi for the treatment of patients with previously untreated extensive-stage ...

AstraZeneca plc with EPIC/TICKER (LON:AZN) had its stock rating noted as ‘Upgrades’ with the recommendation being set at ‘BUY’ today by analysts at Bryan Garnier. AstraZeneca plc are listed in ...